Month: April 2024

FORT WORTH, Texas, April 05, 2024 (GLOBE NEWSWIRE) — RANGE RESOURCES CORPORATION (NYSE: RRC) announced today that its first quarter 2024 financial results news release will be issued Tuesday, April 23 after the close of trading on the New York Stock Exchange. A conference call to review the financial results is scheduled on Wednesday, April 24 at 9:00 a.m. ET (8:00 a.m. CT). A webcast of the call may be accessed at www.rangeresources.com. The webcast will be archived for replay on the Company’s website until May 24, 2024. RANGE RESOURCES CORPORATION (NYSE: RRC) is a leading U.S. independent natural gas and NGL producer with operations focused in the Appalachian Basin. The Company is headquartered in Fort Worth, Texas. More information about Range can be found at www.rangeresources.com. SOURCE: Range Resources Corporation Range...

INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES Declaration pursuant to Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des marchés financiers (AMF)Date of settlementof information Total number of shares Number of shares without voting rights (*) Number of voting rights for threshold calculation (**) Number of actual voting rights (exercisable at shareholders’ meeting)March 31, 2024 20 455 403 696 391 22 376 742 21 680 351February 29, 2024 20 455 403 700 847 22 376 636 21 675 789January 31, 2024 20 455 403 697 328 22 376 636 21 679 308December 31, 2023 20 455 403 701 329 22 376 736 21 675 407(*) exclusively consisting of treasury shares.(**) theoretical voting rights to calculate the threshold crossing including the voting right of treasury shares...

Festi‘s Financial Calendar published on October 25, 2023, has been altered as follows:1Q 2024 23. April 2024 Q1 2024 Results2Q 2024 31. July 2024 Q2 2024 Results3Q 2024 30. October 2024 Q3 2024 Results4Q 2024 5. February 2025 Q4 2024 ResultsAGM 5. March 2025 General MeetingPlease note changed dates for the publication of the Q1 2024 Results, which will take place on April 23, 2024. The financial results will be published after closing of markets each day.   For further information, please contact Ásta S. Fjeldsted, CEO of Festi –  asta@festi.is or Magnús Kr. Ingason, CFO of Festi – mki@festi.is

Company Announcement no. 02-2024 Copenhagen, April 5, 2024  Swiss Properties Invest A/S gives notice to the Annual General Meeting Notice is hereby given to shareholders in Swiss Properties Invest A/S of the ordinary annual general meeting scheduled as follows: Date                Friday, 19th April 2024Time                14:00 (CET)Location          Skovshoved Hotel, Strandvejen 267, 2920 Charlottenlund, Denmark Enclosed you will find notice and agenda for the ordinary annual general meeting.   ABOUT SWISS PROPERTIES INVEST Swiss Properties Invest A/S, which was founded on 8 October 2021, is the Danish holding company of the wholly owned subsidiary Swiss Properties Invest AG (CHE-422.631.240), which was founded on 7 December 2021. The purpose of Swiss Properties Invest AG is to own, operate, optimize, and develop a portfolio of attractive...

Martela Corporation, Stock Exchange Release, 5.4.2024 at 12:00 Martela Corporation’s Annual General Meeting was held on Friday 5.4.2024. The Meeting approved the Financial Statements, discharged the members of the Board of Directors and CEO’s from liability for the year of 2023 and approved remuneration report and new remuneration policy . The Board of Directors proposal that no dividends would be paid was approved. The Annual General Meeting confirmed that the Board of Directors will consist of six members and Mr. Eero Martela, Ms. Hanna Mattila, Mr. Jan Mattsson, Mr. Johan Mild and Ms. Anni Vepsäläinen be re-elected as members of the Board of Directors and a new member Mr. Jacob Kragh. The Annual General Meeting resolved a monthly compensation of EUR 3,700 be paid for the Chairman of the Board and EUR 1,850 for the Board Members,...

5 April 2024 Company Announcement No. 11 Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051. Reponex Pharmaceuticals A/S (Reponex) today announced positive final results from the phase-2 clinical proof-of-concept trial of the drug candidate RNX-051, the MEFO trial, based on received high level summary from the Company’s clinical site. Reponex’s MEFO-trialThis concerns the treatment of patients with right-sided colon cancer and right-sided colon polyps/adenomas (precursors of cancer) with the Company’s drug candidate RNX-051. The company’s clinical collaborators who have performed the trial report the following: BackgroundPatients with precursor lesions to cancer in the colon (adenomas) harbor a different gut...

WiseEye™ AI is Driving AI Innovations for Battery-Powered Endpoint Applications TAINAN, Taiwan, April 05, 2024 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced its participation in the embedded world Exhibition&Conference held in Nuremberg from April 9 to 11, 2024. Himax will showcase its WiseEyeTM applications and AI capabilities at the tinyML Pavilion booth, in collaboration with several ecosystem partners, through interactive demonstrations and expert-led discussions on-site. With Himax’s powerful AI and industry-leading ultralow power technology, battery powered endpoint AI devices can operate with a significantly extended battery life. The exhibition will feature...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California. Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia. Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models. Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib...

Oslo, 5 April 2024: As announced in the fourth quarter 2023 financial report, Scatec has reorganised its segment reporting structure from 1 January 2024. The group’s revenues and operating expenses from the Services segment are now reported as part of the Power Production segment. The merger of the two segments results in an increase of Power Production EBITDA corresponding to the EBITDA previously reported in the Services segment. External revenues from Services are now included in revenues in the Power Production segment, and the net of internal revenues and operating expenses is part of Power Production operating expenses. The estimated increase in Power Production EBITDA for 2024 is 120-130 million, equalling the estimated outlook for Services presented in the fourth quarter 2023 financial report. Following the change, Scatec’s segment...

Serstech AB (publ) meddelar att årsredovisningen för 2023 nu finns tillgänglig på bolagets hemsida https://www.serstech.com/downloads/financial/Arsredovisning2023.pdf, samt som bilaga till detta pressmeddelande. För mer information: Stefan Sandor, VD Serstech ABTelefon: 0739-60 60 67E-post: ss@serstech.com eller Thomas Pileby, Styrelseordförande Serstech ABTelefon: 0702-07 26 43E-post: tp@serstech.com eller besök: www.serstech.com Certified advisor åt Serstech är Svensk Kapitalmarknadsgranskning AB (SKMG). Om SerstechSerstech utvecklare och säljer utrustning för identifiering av farliga kemikalier, såsom narkotika, bomber och kemiska stridsmedel. Bolagets kunder är huvudsakligen rättsvårdande myndigheter och inkluderar FN, Världstullorganisationen (WCO) och tull- och polismyndigheter över hela världen. Serstech har återförsäljare i 63...